DEA issued Order to Show Cause January 3, 2020, for dispensing controlled substances to ten patients without resolving red flags including dangerous high-risk drug combinations; revocation published January 19, 2022.

AARRIC, Inc. d/b/a At Cost RX — DEA Order to Show Cause and Revocation (2018–2022)

Outcome: DEA issued an Order to Show Cause on January 3, 2020, and revoked AARRIC, Inc. d/b/a At Cost RX's DEA Registration No. FA2125640 in a Decision and Order published January 19, 2022, after finding that between February 2018 and September 2019 the pharmacy repeatedly dispensed prescriptions to ten patients without addressing or resolving red flags of potential drug diversion.

AARRIC, Inc. d/b/a At Cost RX was registered with the DEA to handle controlled substances in Schedules II through V under Registration No. FA2125640 at 16970 San Carlos Boulevard, Suite 110, Fort Myers, Florida. The pharmacy was subject to DEA investigation following identification of a pattern of problematic dispensing practices.

The DEA alleged that between February 2018 and September 2019, At Cost RX repeatedly dispensed prescriptions to ten patients without addressing or resolving red flags of potential drug diversion and in contravention of its corresponding responsibility to ensure prescriptions were issued for a legitimate medical purpose. Key red flags included instances where controlled substances were filled in high-risk combinations that significantly elevated the risk for central nervous system and respiratory depression, overdose, coma, and death.

On January 3, 2020, the DEA issued an Order to Show Cause proposing revocation of the pharmacy's registration. Following administrative proceedings, the DEA issued the final Decision and Order, which was published in the Federal Register on January 19, 2022.

Primary Source: AARRIC, Inc. d/b/a At Cost RX; Decision and Order (Fed. Reg. Jan. 19, 2022)